drugset / Trial / NCT00282620

Magnesium to Reduce Implantable Cardioverter Defibrillator (ICD) Shocks and Improve Patient's Quality of Life.

NCT00282620 ↗

Phase 4 Unknown 240 enrolled Hartford Hospital
RandomizedParallel-groupDouble-blindTreatment

Summary

This study is being conducted to see if magnesium can reduce the number of shocks patients with ICDs experience and to see if magnesium supplementation improves patients quality of life.

Timeline

Start
2006-01
Primary completion
—
Completion
2008-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Magnesium L-lactate Unknown — —